{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:40:43Z","timestamp":1780569643867,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually relapse. FLYSYN is an Fc-optimized antibody for eradication of MRD directed to FLT3\/CD135, which is abundantly expressed on AML cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This first-in-human, open-label, single-arm, multicenter trial included AML patients in CR with persisting or increasing MRD and evaluated safety\/tolerability, pharmacokinetics and preliminary efficacy of FLYSYN at different dose levels administered intravenously (cohort 1\u20135: single dose of 0.5\u00a0mg\/m<jats:sup>2<\/jats:sup>, 1.5\u00a0mg\/m<jats:sup>2<\/jats:sup>, 5\u00a0mg\/m<jats:sup>2<\/jats:sup>, 15\u00a0mg\/m<jats:sup>2<\/jats:sup>, 45\u00a0mg\/m<jats:sup>2<\/jats:sup>; cohort 6: 15\u00a0mg\/m<jats:sup>2<\/jats:sup> on day 1, 15 and 29). Three patients were treated per cohort except for cohorts 4 and 6, which were expanded to nine and ten patients, respectively. Primary objective was safety, and secondary efficacy objective was \u2265\u20091 log MRD reduction or negativity in bone marrow.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 31 patients were treated, of whom seven patients (22.6%) experienced a transient decrease in neutrophil count (two grade 3, others \u2264\u2009grade 2). No infusion-related reaction or dose-limiting toxicity was observed. Adverse events (AEs) were mostly mild to moderate, with the most frequent AEs being hematologic events and laboratory abnormalities. Response per predefined criteria was documented in 35% of patients, and two patients maintained MRD negativity until end of study. Application of 45\u00a0mg\/m<jats:sup>2<\/jats:sup> FLYSYN as single or cumulative dose achieved objective responses in 46% of patients, whereas 28% responded at lower doses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>FLYSYN monotherapy is safe and well-tolerated in AML patients with MRD. Early efficacy data are promising and warrant further evaluation in an up-coming phase II trial.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> This clinical is registered on clinicaltrials.gov (NCT02789254).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-023-01490-w","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T03:19:25Z","timestamp":1692242365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease"],"prefix":"10.1186","volume":"16","author":[{"given":"Jonas S.","family":"Heitmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"D\u00f6rfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Kapp-Schwoerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jannik","family":"Labrenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Edelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"M\u00e4rklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichard","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Bethge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane S.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Gro\u00dfe-Hovest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gundram","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"1490_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000486228","volume":"139","author":"X Song","year":"2018","unstructured":"Song X, et al. Incidence, survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: analysis of the surveillance, epidemiology, and end results (SEER) database, 2001\u20132013. Acta Haematol. 2018;139:115\u201327.","journal-title":"Acta Haematol"},{"key":"1490_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"1490_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nrclinonc.2013.100","volume":"10","author":"CS Hourigan","year":"2013","unstructured":"Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol. 2013;10:460\u201371.","journal-title":"Nat Rev Clin Oncol"},{"key":"1490_CR4","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1182\/blood.2020005998","volume":"136","author":"S Kapp-Schwoerer","year":"2020","unstructured":"Kapp-Schwoerer S, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09\u201309 trial. Blood. 2020;136:3041\u201350.","journal-title":"Blood"},{"key":"1490_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","volume":"122","author":"J Kronke","year":"2013","unstructured":"Kronke J, et al. Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia. Blood. 2013;122:100\u20138.","journal-title":"Blood"},{"key":"1490_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/leu.2014.186","volume":"29","author":"T Kohnke","year":"2015","unstructured":"Kohnke T, et al. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia. 2015;29:377\u201386.","journal-title":"Leukemia"},{"key":"1490_CR7","first-page":"356","volume":"2016","author":"G Ossenkoppele","year":"2016","unstructured":"Ossenkoppele G, Schuurhuis GJ. MRD in AML: Does it already guide therapy decision-making? Hematol Am Soc Hemat. 2016;2016:356\u201365.","journal-title":"Hematol Am Soc Hemat"},{"key":"1490_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11899-015-0260-7","volume":"10","author":"S Kayser","year":"2015","unstructured":"Kayser S, Walter RB, Stock W, Schlenk RF. Minimal residual disease in acute myeloid leukemia\u2013current status and future perspectives. Curr Hematol Malig Rep. 2015;10:132\u201344.","journal-title":"Curr Hematol Malig Rep"},{"key":"1490_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/M19-2936","volume":"172","author":"GB McDonald","year":"2020","unstructured":"McDonald GB, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003\u20132007 versus 2013\u20132017 cohorts. Ann Intern Med. 2020;172:229\u201339.","journal-title":"Ann Intern Med"},{"key":"1490_CR10","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","volume":"383","author":"AH Wei","year":"2020","unstructured":"Wei AH, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383:2526\u201337.","journal-title":"N Engl J Med"},{"key":"1490_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri2744","volume":"10","author":"LM Weiner","year":"2010","unstructured":"Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010;10:317\u201327.","journal-title":"Nat Rev Immunol"},{"key":"1490_CR12","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin\u2019s lymphoma. Blood. 1997;90:2188\u201395.","journal-title":"Blood"},{"key":"1490_CR13","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/jcm8081261","volume":"8","author":"BA Williams","year":"2019","unstructured":"Williams BA, et al. Antibody therapies for acute myeloid leukemia: unconjugated, toxin-conjugated, radio-conjugated and multivalent formats. J Clin Med. 2019;8:1261.","journal-title":"J Clin Med"},{"key":"1490_CR14","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","volume":"23","author":"EJ Feldman","year":"2005","unstructured":"Feldman EJ, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23:4110\u20136.","journal-title":"J Clin Oncol"},{"key":"1490_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","volume":"11","author":"J Baron","year":"2018","unstructured":"Baron J, Wang ES. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11:549\u201359.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1490_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00062752-200105000-00004","volume":"8","author":"HJ McKenna","year":"2001","unstructured":"McKenna HJ. Role of hematopoietic growth factors\/FLT3 ligand in expansion and regulation of dendritic cells. Curr Opin Hematol. 2001;8:149\u201354.","journal-title":"Curr Opin Hematol"},{"key":"1490_CR17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nrc1169","volume":"3","author":"DL Stirewalt","year":"2003","unstructured":"Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003;3:650\u201365.","journal-title":"Nat Rev Cancer"},{"key":"1490_CR18","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/ni.1615","volume":"9","author":"C Waskow","year":"2008","unstructured":"Waskow C, et al. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat Immunol. 2008;9:676\u201383.","journal-title":"Nat Immunol"},{"key":"1490_CR19","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood.V87.3.1089.bloodjournal8731089","volume":"87","author":"CE Carow","year":"1996","unstructured":"Carow CE, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1\/Flk2) in human leukemias. Blood. 1996;87:1089\u201396.","journal-title":"Blood"},{"key":"1490_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299\u2013312.","journal-title":"Leukemia"},{"key":"1490_CR21","first-page":"238","volume":"10","author":"O Rosnet","year":"1996","unstructured":"Rosnet O, et al. Human FLT3\/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia. 1996;10:238\u201348.","journal-title":"Leukemia"},{"key":"1490_CR22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1038\/leu.2011.372","volume":"26","author":"M Hofmann","year":"2012","unstructured":"Hofmann M, et al. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia. 2012;26:1228\u201337.","journal-title":"Leukemia"},{"key":"1490_CR23","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.1200\/jco.2015.33.15_suppl.7059","volume":"33","author":"D Sanford","year":"2015","unstructured":"Sanford D, et al. Efficacy and safety of an anti-FLT3 antibody (LY3012218) in patients with relapsed acute myeloid leukemia. J Clin Oncol. 2015;33:7059.","journal-title":"J Clin Oncol"},{"key":"1490_CR24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nbt1137","volume":"23","author":"GP Adams","year":"2005","unstructured":"Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147\u201357.","journal-title":"Nat Biotechnol"},{"key":"1490_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503\u201310.","journal-title":"Nat Immunol"},{"key":"1490_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fimmu.2013.00076","volume":"4","author":"UJ Seidel","year":"2013","unstructured":"Seidel UJ, Schlegel P, Lang P. Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol. 2013;4:76.","journal-title":"Front Immunol"},{"key":"1490_CR27","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1073\/pnas.0508123103","volume":"103","author":"GA Lazar","year":"2006","unstructured":"Lazar GA, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA. 2006;103:4005\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1490_CR28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2003-07-2585","volume":"104","author":"Y Li","year":"2004","unstructured":"Li Y, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood. 2004;104:1137\u201344.","journal-title":"Blood"},{"key":"1490_CR29","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1490_CR30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"1490_CR31","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","volume":"5","author":"M Heuser","year":"2021","unstructured":"Heuser M, et al. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv. 2021;5:2294\u2013304.","journal-title":"Blood Adv"},{"key":"1490_CR32","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","volume":"29","author":"J Kronke","year":"2011","unstructured":"Kronke J, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011;29:2709\u201316.","journal-title":"J Clin Oncol"},{"key":"1490_CR33","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","volume":"132","author":"F Thol","year":"2018","unstructured":"Thol F, et al. Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood. 2018;132:1703\u201313.","journal-title":"Blood"},{"key":"1490_CR34","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"1490_CR35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.it.2007.07.011","volume":"28","author":"AS De Groot","year":"2007","unstructured":"De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28:482\u201390.","journal-title":"Trends Immunol"},{"key":"1490_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493\u2013507.","journal-title":"Clin Pharmacokinet"},{"key":"1490_CR37","first-page":"134","volume":"15","author":"D Romero","year":"2018","unstructured":"Romero D. Haematological cancer: improved sensitivity in MRD detection. Nat Rev Clin Oncol. 2018;15:134.","journal-title":"Nat Rev Clin Oncol"},{"key":"1490_CR38","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3389\/fonc.2019.00689","volume":"9","author":"I Del Giudice","year":"2019","unstructured":"Del Giudice I, et al. Minimal residual disease in chronic lymphocytic leukemia: A new goal? Front Oncol. 2019;9:689.","journal-title":"Front Oncol"},{"key":"1490_CR39","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3389\/fonc.2019.00655","volume":"9","author":"MT Voso","year":"2019","unstructured":"Voso MT, et al. MRD in AML: the role of new techniques. Front Oncol. 2019;9:655.","journal-title":"Front Oncol"},{"key":"1490_CR40","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101\u201310.","journal-title":"N Engl J Med"},{"key":"1490_CR41","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23:1055\u201365.","journal-title":"Lancet Oncol"},{"key":"1490_CR42","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, et al. Glofitamab, a novel, bivalent CD20-Targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory b-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39:1959\u201370.","journal-title":"J Clin Oncol"},{"key":"1490_CR43","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, et al. Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021;398:665\u201374.","journal-title":"Lancet"},{"key":"1490_CR44","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med"},{"key":"1490_CR45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"1490_CR46","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32:4134\u201340.","journal-title":"J Clin Oncol"},{"key":"1490_CR47","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","volume":"28","author":"C Sommer","year":"2020","unstructured":"Sommer C, et al. Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Mol Ther. 2020;28:2237\u201351.","journal-title":"Mol Ther"},{"key":"1490_CR48","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/bjh.16722","volume":"192","author":"IS Tiong","year":"2021","unstructured":"Tiong IS, et al. Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. Br J Haematol. 2021;192:1026\u201330.","journal-title":"Br J Haematol"},{"key":"1490_CR49","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol. 2018;19:1668\u201379.","journal-title":"Lancet Oncol"},{"key":"1490_CR50","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood-2022-159503","volume":"140","author":"J Othman","year":"2022","unstructured":"Othman J, et al. High molecular response rate and overall survival with FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in AML. Blood. 2022;140:2002\u20134.","journal-title":"Blood"},{"key":"1490_CR51","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1002\/ijc.25635","volume":"128","author":"BJ Schmiedel","year":"2011","unstructured":"Schmiedel BJ, et al. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation. Int J Cancer. 2011;128:2911\u201322.","journal-title":"Int J Cancer"},{"key":"1490_CR52","doi-asserted-by":"publisher","first-page":"440","DOI":"10.4161\/mabs.12203","volume":"2","author":"MK Sutherland","year":"2010","unstructured":"Sutherland MK, et al. 5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs. 2010;2:440\u20138.","journal-title":"MAbs"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01490-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01490-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01490-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T18:22:08Z","timestamp":1700418128000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01490-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01490-w","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the leading ethics committee of the University Hospital T\u00fcbingen (184\/2016AMG1), local ethics committees and the Paul Ehrlich Institute (2893). The trial was registered on clinicaltrials.gov (NCT02789254) and EudraCT number 2016-000236-17.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients provided written informed consent prior to enrolment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"JSH received financial support for travel expenses by Synimmune GmbH. RFS received financial support for consulting Daiichi Sankyo, Pfizer; for speakers' Bureau by Pfizer, Daiichi Sankyo, Novartis; travel expenses by Daiichi Sankyo; research funding by PharmaMar, AstraZeneca, Pfizer, Daiichi Sankyo, Roche. MH received honoraria from Abbvie, Eurocept, Jazz Pharmaceuticals, Janssen, Novartis, Takeda; financial support for consulting or advisory role by Abbvie, Agios, BMS, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Kura Oncology, Novartis, Pfizer, PinotBio, Roche, Tolremo, for research funding to institution by Abbvie, Agios, Astellas, Bayer Pharma AG, BergenBio, Daiichi Sankyo, Glycostem, Jazz Pharmaceuticals, Loxo Oncology, Novartis, Pfizer, PinotBio, Roche. FT received financial support for consulting or advisory Role by Daiichi Sankyo, Pfizer, Abbvie, Celgene, Astellas. GJ for consulting or advisory role by Synimmune, GmbH. HRS received financial support for consulting or advisory board membership by BMS, Celgene, Novartis, Pfizer, Roche, Synimmune GmbH; HRS received research funding to institution by ABL Bio, Celgene, Novartis, Synimmune GmbH. GJ, LGH and MS are shareholders of Synimmune GmbH. DE received lecture fees by Pfizer. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}